文献速递冠心病心力衰竭与心肌病

高敏心肌肌钙蛋白的临床解读与新方向:检出不等于诊断

Interpreting High-Sensitivity Cardiac Troponin in Clinical Practice and Emerging Directions: Detection Is No Longer Diagnosis.
PubMed 文献 · J Am Coll Cardiol · 2026-10-28

本文是一篇叙述性综述,探讨高敏心肌肌钙蛋白检测普及后心肌损伤的分类难题。文章提出准确分类不能依赖算法,而需基于检测特性、连续检测、心梗通用定义及非 ACS 病因四个维度的整合解读。同时梳理了肌钙蛋白生物学研究的新方向,强调当前解读责任仍在临床医生。

要点

  • 非缺血性心肌损伤常被误标为继发性心梗,导致心梗过度诊断。
  • 慢性心肌损伤的后续心梗或心血管死亡风险接近原发性心梗,但常被忽视。
  • 肌钙蛋白升高需结合四个维度整合解读,不能单纯依赖算法分类。

核心结论

  • 准确分类心肌损伤不能委托给算法,需要基于四个领域的整合、情境化解读。
  • 慢性心肌损伤一旦排除梗死,其后续心梗或心血管死亡风险接近原发性心梗,不应被忽视。
  • 在检测本身承担更多解读负担之前,临床医生仍需承担解读责任。

研究设计与样本

  • 本文为叙述性综述,未报告系统检索策略或纳入排除标准。

主要发现

  • 肌钙蛋白浓度异常在多种心脏及全身性疾病中常见,当代核心挑战是正确分类而非检测。
  • 分类错误双向发生:非缺血性心肌损伤常被误标为继发性心梗,慢性心肌损伤则常被忽视。
  • 肌钙蛋白在慢性肾病、心衰、脓毒症、快速性心律失常、肺栓塞、应激性心肌病等非 ACS 情况中升高属预期现象。

关键数值与推荐

  • 解读需整合四个领域:hs-cTnI 与 hs-cTnT 的分析与生物学特性,含检测特异性与性别特异性阈值、清除动力学、分析干扰与假阳性来源。
  • 连续检测策略包括欧洲心脏病学会 0/1 小时与 0/2 小时算法、床旁平台及人工智能决策支持,各有能力与局限。
  • 心梗分类依据第五版心肌梗死通用定义,需区分心肌损伤、坏死与梗死,以及诊断与风险分层。

临床怎么用

  • 对疑似继发性心梗、观察区及无动态变化模式的肌钙蛋白升高,应结合情境解读而非机械套用流程。
  • 慢性心肌损伤即使排除梗死,也应识别其后续事件高风险并给予相应关注。

局限性

  • 本文未报告系统检索方法,可能存在文献选择偏倚。
  • 文中提出的解读框架和床旁指导未经过前瞻性临床验证。
  • 肌钙蛋白生物学研究方向尚处于探索阶段,文中未提供其转化为临床应用的具体时限或有效性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-sensitivity cardiac troponin (hs-cTn) assays have solved the problem of detecting myocardial injury and, in doing so, created the problem of classifying it. Abnormal troponin concentrations are now known to be common across a wide spectrum of cardiac and systemic disease, and the central challenge of contemporary practice is no longer whether myocardial injury can be detected, but whether it can be correctly classified. Misclassification occurs in both directions and with real consequence: nonischemic myocardial injury is frequently mislabeled as secondary myocardial infarction (MI), contributing to the overdiagnosis of MI, and chronic myocardial injury, which carries a risk of subsequent MI or cardiovascular death approaching that of primary MI, is routinely dismissed once infarction has been excluded. This narrative review argues that accurate classification cannot be delegated to an algorithm and instead requires integrated, context-aware interpretation grounded in 4 domains: 1) the analytical and biological properties of hs-cTnI and hs-cTnT, including assay-specific and sex-specific thresholds, clearance kinetics, and sources of analytical interference and false-positive results; 2) the capabilities and limitations of guideline-endorsed serial testing, including the European Society of Cardiology 0/1h and 0/2h algorithms, point-of-care platforms, and artificial intelligence-based decision support; 3) rigorous application of the Fifth Universal Definition of Myocardial Infarction, in particular the distinctions between myocardial injury, necrosis, and infarction, and between diagnosis and risk stratification; and 4) recognition of the non-acute coronary syndrome conditions-chronic kidney disease, heart failure, sepsis, tachyarrhythmias, pulmonary embolism, takotsubo syndrome, and others-in which troponin elevation is expected rather than anomalous. We provide explicit bedside guidance for the situations that clinicians find most difficult, including suspected secondary MI, the observe zone, and troponin elevation without a dynamic pattern. Finally, we review emerging understanding of troponin biology, clearance, proteolysis and fragmentation, macrotroponin, antitroponin autoantibodies, and extracellular vesicle-associated troponin, which may eventually allow the assay itself to carry more of the interpretive burden. Until then, that burden rests with the clinician.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Spanos, Januzzi. Interpreting High-Sensitivity Cardiac Troponin in Clinical Practice and Emerging Directions: Detection Is No Longer Diagnosis. J Am Coll Cardiol. 2026. PMID: 42949674. doi:10.1016/j.jacc.2026.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。